New Zealand markets closed

Teva Pharmaceutical Industries Limited (TEVA)

NYSE - Nasdaq Real-time price. Currency in USD
Add to watchlist
9.080.00 (0.00%)
As of 11:31AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close9.08
Open8.99
Bid9.04 x 1100
Ask9.05 x 900
Day's range8.86 - 9.09
52-week range7.23 - 11.55
Volume2,959,917
Avg. volume9,049,619
Market cap10.082B
Beta (5Y monthly)1.18
PE ratio (TTM)N/A
EPS (TTM)-0.56
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend date27 Nov 2017
1y target est10.17
  • Business Wire

    Teva Reaches Agreement With West Virginia to Settle the State’s Opioid-Related Claims

    TEL AVIV, Israel & PARSIPPANY, N.J., May 25, 2022--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and its affiliates, has reached an agreement with the Attorney General of West Virginia that settles the state’s and its subdivisions opioid-related claims. The settlement will provide West Virginia with $75 million over 15 years in addition to $8 million in attorneys’ fees and costs incurred during the trial. Teva will also provide its life-savin

  • Business Wire

    Teva Presents New Long-Term AUSTEDO® (deutetrabenazine) Tablets Data at 2022 American Psychiatric Association Annual Meeting

    TEL AVIV, Israel & PARSIPPANY, N.J., May 23, 2022--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced new efficacy and safety data from a 3-year open-label extension (OLE) study on AUSTEDO® (deutetrabenazine) tablets in postmenopausal women with tardive dyskinesia (TD). These data will be presented at the 2022 American Psychiatric Association (APA) Annual Meeting, held May 21-25 in New Orleans and online June 7-10. In addition, ne

  • Business Wire

    United Kingdom first to grant licence for Teva’s ophthalmology biosimilar Ongavia (ranibizumab)▼

    AMSTERDAM, May 17, 2022--Teva Pharmaceutical Industries Ltd welcomes the UK Medicines & Healthcare Regulatory Agency (MHRA) decision to grant a licence for Ongavia®, a biosimilar to Lucentis® (ranibizumab ), an eye injection. The United Kingdom is the first country in Europe to authorize commercialization of Ongavia® for the treatment of neovascular (wet) age-related macular degeneration ("AMD"). Ongavia® is also licenced for: the treatment of visual impairment due to diabetic macular oedema (DM